37. Hepatitis B: Current and Future Challenges in Treatment and Prevention
Thursday, October 4, 2018: 10:30 AM-11:45 AM
Room: N 25

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss current standard of care management and treatment of HBV infection
  • review challenges of current HBV vaccine, approach to waning immunity and immunocompromised hosts, and investigational vaccines on the horizon
  • discuss new approaches to HBV treatment and most recent developments in drug discovery

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, HIV clinicians, HIV specialists, Infectious diseases pediatricians, Infectious diseases physicians, Medical students and residents, Members-in-training, Nurses, Pharmacists, Public health practitioners, Researchers, Scientists, Vaccinologists

Tracks: Pediatric ID, Adult ID, HIV-STD-TB

Moderators:  Susanna Naggie, MD, MHS, Duke University Medical Center, Duke Clinical Research Institute and Ravi Jhaveri, MD, University of North Carolina

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-18-200-L01-P


S. Naggie, Gilead: Investigator , Research grant . AbbVie: Investigator , Research support . Janssen: Investigator , Research support . Merck: Investigator , Research support . Tacere: Investigator , Research support .

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.